The Evaluating Multidisciplinary Bone Marrow Failure Care in Bone Marrow Failure and Related Disorders.

Aplastic Anemia Clinical Trial

— EMBRACE  

Official title:

The Evaluating Multidisciplinary Bone Marrow Failure Care in Bone Marrow Failure and Related Disorders.(The EMBRACE Study)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04819607
• Other study ID #: 21/44
• Status: Recruiting
• Start date: June 9, 2021
• Est. completion date: April 2024

Study information

• Verified date: August 2021
• Source: Peter MacCallum Cancer Centre, Australia
• Contact: Mary Panjari, PhD
• Phone: 03 8559 5000
• Email: mary.panjari[@]petermac.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a prospective hybrid implementation-effectiveness study of a model of care for patients with bone marrow failure syndromes and inherited predisposition to haematological malignancy that includes comprehensive diagnostic genomic evaluation, multidisciplinary case review, provision of clinical care including from clinical haematologists, medical geneticists and genetic counsellors.

Description:

The inherited bone marrow disorders (IBMD) comprise both the traditional inherited bone marrow failure syndromes (BMFS) and the more recently described entity of germline predisposition to haematological malignancy. Patients with IBMD often present highly complex health issues that are unique and not commonly encountered. As a consequence, clinicians may feel less confident in managing these unique issues given their lack of frequent exposure to this patient group. Recent advances in genomics have resulted in more accurate diagnosis of IBMD and their subtyping and have resulted in a rapidly evolving field with multiple opportunities to improve patient outcomes.

Stage 1 of this study evaluated and quantified the current challenges faced by 3 stakeholder groups, patients with IBMD, patient advocates and nationally, clinicians who care for IBMD patients. The results demonstrated that the challenges described in Stage 1 may be overcome by instigating a multidisciplinary approach to care for BMF patients. Interventions designed to address the challenges identified in stage 1 form the model of multidisciplinary care to be implemented in the Peter MacCallum Cancer Centre/ Royal Melbourne Hospital clinic. The model of care involves:

1. Provide access to genetic testing with expert result interpretation

2. Presentation of clinical information and relevant investigations (including genetic) at a multidisciplinary team meeting involving haematologists, molecular haematopathologists, clinical genetics, genetic counsellors, scientists and specialised nurses.

3. Provision of a suggested care plan to clinician

4. Genetic counselling and provision of written disease specific information including details of suggested care plan to patient

5. Genetic counselling and provision of written information and access to testing for at risk family members

6. Dedicated team focused on many individually rare diseases with a demonstrated focus on provision of comprehensive care

7. Opportunity to participate in local and international research

The EMBRACE study will focus on evaluating the model of care.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: April 2024
• Est. primary completion date: April 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Patients must meet all the following criteria for study entry:

1. Age > or = 18 years at enrolment

2. Able to give informed consent (or responsible family member able to give informed consent)

3. Patient is receiving care under the institutional guidelines/stream model of care

Exclusion Criteria:

1. Patient not eligible for management under the model of care

Related Conditions & MeSH terms

• Anemia, Aplastic
• Aplastic Anemia
• Bone Marrow Failure Syndrome
• Pancytopenia

Intervention

Other:
• model of care
Multidisciplinary model of care for BMFS patients.

Locations

Country	Name	City	State
Australia	Peter MacCallum Cancer Centre	Melbourne	Victoria

Sponsors (1)

Lead Sponsor	Collaborator
Peter MacCallum Cancer Centre, Australia

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	to assess the effectiveness and implementation of the model of care through a mixture of objective metrics and patient /physician reported outcomes	Effectiveness - patient/physician reported outcomes of satisfaction with model of care as measured by questionnaire Implementation - compliance with of model as measured by audit against pre-specified key performance indicators	12 months
Secondary	To assess longitudinal quality of life assessment in patients being treated with the model	Longitudinal quality of life assessment in patients being treated with the model measured by the EORTC QLQ-C30	12 months
Secondary	To quantitate healthcare usage of patients within the model	Quantitate healthcare usage of patients within the model measured by questionnaire	12 months